| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.270.24.14505 |
| P698 | PubMed publication ID | 7540171 |
| P2093 | author name string | H Nakai | |
| P Lollar | |||
| L W Hoyer | |||
| E L Saenko | |||
| J F Healey | |||
| D Scandella | |||
| I M Lubin | |||
| P2860 | cites work | DNA sequencing with chain-terminating inhibitors | Q22066207 |
| Molecular cloning of a cDNA encoding human antihaemophilic factor | Q28268498 | ||
| A hot spot of binding energy in a hormone-receptor interface | Q29547547 | ||
| On the attribution of binding energy in antigen-antibody complexes McPC 603, D1.3, and HyHEL-5. | Q30195996 | ||
| Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli | Q33641665 | ||
| Inhibition of human factor VIIIa by anti-A2 subunit antibodies | Q34151336 | ||
| A simple method for the preparation of homogeneous phospholipid vesicles | Q34405356 | ||
| Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid | Q34575122 | ||
| Epitopes on protein antigens: misconceptions and realities. | Q36576238 | ||
| Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments | Q37555695 | ||
| Antibody-antigen complexes | Q37943232 | ||
| The antigenic structure of proteins: a reappraisal. | Q40076398 | ||
| Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase. | Q45787056 | ||
| Thermodynamic analysis of an antibody functional epitope | Q46460317 | ||
| Additivity of mutational effects in proteins | Q46528565 | ||
| Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. | Q52485676 | ||
| High resolution functional analysis of antibody-antigen interactions | Q67541557 | ||
| Gene splicing by overlap extension | Q70662421 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 14505-14509 | |
| P577 | publication date | 1995-06-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII | |
| P478 | volume | 270 |
| Q48152338 | A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor. |
| Q36250957 | A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function |
| Q36825812 | A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII. |
| Q45884403 | Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis |
| Q37382199 | B-cell and T-cell epitopes in anti-factor VIII immune responses |
| Q37378510 | Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies. |
| Q36412125 | Characterization of factor VIII inhibitors |
| Q73693365 | Cleavage of factor VIII heavy chain is required for the functional interaction of a2 subunit with factor IXA |
| Q34304145 | Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation. |
| Q36851942 | Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation |
| Q30481770 | Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog |
| Q38632876 | Engineering less immunogenic and antigenic FVIII proteins |
| Q38735281 | Evidence That Factor VIII Forms a Bivalent Complex with the Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1): IDENTIFICATION OF CLUSTER IV ON LRP1 AS THE MAJOR BINDING SITE. |
| Q34964772 | Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors |
| Q36412120 | Factor VIII structure and function |
| Q45867739 | Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. |
| Q30577011 | High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance |
| Q73066606 | Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa |
| Q51831475 | Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. |
| Q45876257 | In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic |
| Q44274593 | Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. |
| Q31056138 | Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. |
| Q30707748 | Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients |
| Q34983308 | Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors? |
| Q35793113 | PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice |
| Q36951675 | Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. |
| Q41665286 | Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition |
| Q80273707 | Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain |
| Q84156772 | The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice |
| Q36743356 | The diversity of the immune response to the A2 domain of human factor VIII |
| Q27648918 | The tertiary structure and domain organization of coagulation factor VIII |
| Q42864630 | Use of affinity-directed liquid chromatography-mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction |
| Q33650193 | Why do inhibitors arise in patients with haemophilia A? |
Search more.